Patents by Inventor Barry Kiely

Barry Kiely has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20230405061
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Application
    Filed: July 14, 2023
    Publication date: December 21, 2023
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Barry KIELY, Eileen Frances MURPHY, David GROEGER
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20230210921
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Applicant: PrecisionBiotics Group Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER
  • BIFIDOBACTERIUM LONGUM
    Publication number: 20230106819
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of an infection in a subject caused by a coronavirus such as SARS-CoV-2. They are also useful in the prophylaxis of a secondary bacterial infection associated with an infection in a subject caused by a coronavirus, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: March 12, 2021
    Publication date: April 6, 2023
    Inventors: David GROEGER, Barry KIELY
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11590179
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 28, 2023
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
    Patent number: 11529381
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 20, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Liam O'Mahony, David Groeger
  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20220387523
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with LBS.
    Type: Application
    Filed: June 17, 2022
    Publication date: December 8, 2022
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Barry KIELY, Eileen Frances Murphy, David Groeger
  • for treating obesity and associated metabolic disorders
    Patent number: 11490643
    Abstract: The strain Lactobacillus casei AH077 (NCIMB12019) produces a polysaccharide and increases energy excretion. The strain acts to block fat absorption and is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: November 8, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Eileen Frances Murphy, Selena Healy
  • Combination product for prophylaxis and treatment of irritable bowel syndrome
    Patent number: 11400123
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 2, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Eileen Frances Murphy, David Groeger
  • PROBIOTIC BIFIDOBACTERIUM STRAIN
    Publication number: 20220169976
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Application
    Filed: December 8, 2021
    Publication date: June 2, 2022
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • Probiotic strain
    Patent number: 11225641
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: January 18, 2022
    Assignee: PrecisionBiotics Group Limited
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • LACTOBACILLUS CASEI FOR TREATING OBESITY AND ASSOCIATED METABOLIC DISORDERS
    Publication number: 20210282444
    Abstract: The strain Lactobacillus casei AH077 (NCIMB12019) produces a polysaccharide and increases energy excretion. The strain acts to block fat absorption and is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 16, 2021
    Applicant: PrecisionBiotics Group Limited
    Inventors: Barry KIELY, Eileen Frances MURPHY, Selena HEALY
  • for treating obesity and associated metabolic disorders
    Patent number: 10973862
    Abstract: Bifidobacterium longum AH1362 (NCIMB 41715) produces a polysaccharide and increases energy excretion. The strain is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 13, 2021
    Assignee: PrecisionBiotics Group Limited
    Inventors: Barry Kiely, Eileen Frances Murphy, Selena Healy
  • PROBIOTIC BIFIDOBACTERIUM STRAIN
    Publication number: 20200325548
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 15, 2020
    Applicant: PRECISIONBIOTICS GROUP LIMITED
    Inventors: Liam O'MAHONY, Barry KIELY, John Francis CRYAN, Timothy DINAN, Eileen Frances MURPHY
  • COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20200289586
    Abstract: A combination product comprising a strain of Bifidobacterium NCIMB 41676 and a strain of Bifidobacterium NCIMB 41003 is used in the prophylaxis or treatment of irritable bowel syndrome (IBS). The combination product leads to a surprising, sustained positive effects, even after feeding has stopped.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 17, 2020
    Inventors: Barry KIELY, Eileen Frances MUEPHY, David GROEGER
  • A COMBINATION PRODUCT FOR PROPHYLAXIS AND TREATMENT OF IRRITABLE BOWEL SYNDROME
    Publication number: 20200289587
    Abstract: A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 17, 2020
    Inventors: Barry KIELY, Eileen Frances MURPHY, David GROEGER
  • BIFIDOBACTERIUM LONGUM
    Publication number: 20200115685
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 16, 2020
    Applicant: Alimentary Health Ltd.
    Inventors: Jose Carlos GARCIA-GARCIA, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony
  • Probiotic bifidobacterium strain
    Patent number: 10597739
    Abstract: Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: March 24, 2020
    Assignee: PrecisionBiotics Group Limited
    Inventors: Liam O'Mahony, Barry Kiely, John Francis Cryan, Timothy Dinan, Eileen Frances Murphy
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200016220
    Abstract: Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 16, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER, Raymond Alan GRANT, David MICHALOVICH, Edith M. HESSEL, Richard A. WILLIAMSON
  • BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION
    Publication number: 20200000859
    Abstract: An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Applicant: Alimentary Health Limited
    Inventors: Barry KIELY, Liam O'MAHONY, David GROEGER
  • Patent number: 10519430
    Abstract: A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 31, 2019
    Assignee: Alimentary Health Ltd.
    Inventors: Jose Carlos Garcia-Garcia, Michael John Janusz, Barry Kiely, Eileen Frances Murphy, Liam O'Mahony